Cargando…

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations

OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi‐national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bancroft, Elizabeth K., Saya, Sibel, Page, Elizabeth C., Myhill, Kathryn, Thomas, Sarah, Pope, Jennifer, Chamberlain, Anthony, Hart, Rachel, Glover, Wayne, Cook, Jackie, Rosario, Derek J., Helfand, Brian T., Hutten Selkirk, Christina, Davidson, Rosemarie, Longmuir, Mark, Eccles, Diana M., Gadea, Neus, Brewer, Carole, Barwell, Julian, Salinas, Monica, Greenhalgh, Lynn, Tischkowitz, Marc, Henderson, Alex, Evans, David Gareth, Buys, Saundra S., Eeles, Rosalind A., Aaronson, Neil K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Urological Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378691/ https://www.ncbi.nlm.nih.gov/pubmed/29802810 http://dx.doi.org/10.1111/bju.14412

Ejemplares similares

Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants
por: Dias, Alexander, et al.
Publicado: (2023)

Corrigendum to “Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study” [Eur Urol 2014;66:489–99]
por: Bancroft, Elizabeth K., et al.
Publicado: (2015)

Prostate Cancer Risks for Male BRCA1 [Image: see text] and BRCA2 Mutation Carriers: A Prospective Cohort Study()
por: Nyberg, Tommy, et al.
Publicado: (2020)

Prostate Cancer Risk by BRCA2 Genomic Regions
por: Nyberg, Tommy, et al.
Publicado: (2020)

Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status
por: Killick, Emma, et al.
Publicado: (2014)

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study
por: Girardi, Fabio, et al.
Publicado: (2018)

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
por: Bancroft, Elizabeth K., et al.
Publicado: (2014)

BRCA1, BRCA2 and their possible function in DNA damage response
por: Kote-Jarai, Z, et al.
Publicado: (1999)

Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage
por: Kote-Jarai, Z, et al.
Publicado: (2008)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

Assessing BRCA1 activity in DNA damage repair using human induced pluripotent stem cells as an approach to assist classification of BRCA1 variants of uncertain significance
por: Ozgencil, Meryem, et al.
Publicado: (2021)

Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers
por: Eeles, Rosalind A
Publicado: (2000)

BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis
por: Nyberg, Tommy, et al.
Publicado: (2021)

BRCA1 polymorphisms.
por: Campbell, I. G., et al.
Publicado: (1997)

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
por: Page, Elizabeth C., et al.
Publicado: (2019)

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
por: Mavaddat, Nasim, et al.
Publicado: (2020)

When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges
por: Speight, Beverley, et al.
Publicado: (2017)

Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives
por: Ardern-Jones, Audrey, et al.
Publicado: (2010)

Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
por: Mavaddat, Nasim, et al.
Publicado: (2020)

Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls
por: Locke, Imogen, et al.
Publicado: (2007)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
por: McCrorie, Alan D, et al.
Publicado: (2020)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
por: Cline, Melissa S., et al.
Publicado: (2018)

The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations
por: Terry, Mary Beth, et al.
Publicado: (2019)

BRCA1 mutations in southern England.
por: Eccles, D. M., et al.
Publicado: (1998)

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants
por: Li, Shuai, et al.
Publicado: (2022)

Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer
por: Moynihan, C., et al.
Publicado: (2017)

Management of Breast Cancer in BRCA1/2 Mutation Carriers
por: Eeles, R. A., et al.
Publicado: (1999)

Understanding of BRCA VUS genetic results by breast cancer specialists
por: Eccles, B. K., et al.
Publicado: (2015)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Prediction of the functional impact of missense variants in BRCA1 and BRCA2 with BRCA-ML
por: Hart, Steven N., et al.
Publicado: (2020)

Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices
por: Toland, Amanda Ewart, et al.
Publicado: (2018)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families
por: Choi, Yun-Hee, et al.
Publicado: (2021)

Mutation analysis of PALB2 in BRCA1 and BRCA2-negative breast and/or ovarian cancer families from Eastern Ontario, Canada
por: Hartley, Taila, et al.
Publicado: (2014)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

Breast Cancer Risk Perceptions among Relatives of Women with Uninformative Negative BRCA1/2 Test Results: The Moderating Effect of the Amount of Shared Information
por: Himes, Deborah O., et al.
Publicado: (2015)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers
por: Maia, Ana-Teresa, et al.
Publicado: (2012)

The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women
por: Larionov, Alexey, et al.
Publicado: (2023)

BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial
por: Kote-Jarai, Z, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_3la10nof11bkcja2998mknkaa9